Timothy Wilens, MD is the Chief of the Division of Child and Adolescent Psychiatry at MGH and the Co-Director of the Center for Addiction Medicine. He is the MGH Trustees Chair in Addiction Medicine and a Professor of Psychiatry at Harvard Medical School. Dr. Wilens’ research interests include the relationship among ADHD, bipolar disorder, and substance use disorders; embedded health care models, and the pharmacotherapy of ADHD across the lifespan.
-
Study of nearly 8,000 patients finds telehealth prescribing of ADHD stimulants does not increase risk of substance use disorder; however,risk of stimulant use disorder may […] -
A randomized controlled trial looks at centanafadine, a novel norepinephrine, dopamine, serotonin reuptake inhibitor, for the treatment of ADHD in adolescents. -
A national leader in the field, Dr. Wilens will begin his term following AACAP’s 2025 Annual Meeting—helping shape the future of mental health care for […] -
Children and adolescents with ADHD who have three or more symptoms are at significantly higher risk for initiating nicotine and tobacco use, while those with […] -
The fully updated and expanded third edition will continue to be an essential resource for all psychiatrists and mental health providers. -
Earlier initiation of treatment and longer duration of stimulant therapy for ADHD were associated with lower risk for prescription stimulant misuse and/or cocaine use in […]